WORLDWIDE REGISTRATION

Dolutegravir 5 mg Dispersible Tablets

APPROVAL

Argentina	Ghana	Tr
Australia	Israel	Τι
Botswana	Kazakhstan	U
Brazil	Kenya	U
Cameroon	Malawi	U
Canada	Mexico	U
Chile	Namibia	U
China	Niger	Za
Colombia	Peru	Zi
Cote d'Ivoire	Singapore	
DRC	South Africa	
Ecuador	Switzerland	
EU	Tanzania	
Gabon	Thailand	

Trinidad & Tobago Turkey Uganda UK Uruguay USA Uzbekistan Zambia Zimbabwe

SUBMISSION

Burkina Faso	Nigeria
China	Senegal
Egypt	UAE
Ethiopia	Ukraine
Malaysia	
Mozambique	

- "Approval" means: Marketing Authorisation has been granted by a country or there is no formal regulatory process in place, in the relevant country.
- "Submission" means: A registration dossier has been submitted to local authority for review in the relevant country. Please note, Submission does not guarantee that a Marketing Authorisation will be granted.
- Granted Marketing Authorisations may include limitations on the use of the product.

This document was prepared on 02 Apr 2024 and will be updated on a quarterly basis by ViiV Healthcare. It is made available for information purposes only and ViiV Healthcare accepts no liability arising from the reliance by third parties, on the information provided.